PureTech Health Says FDA Has Given Fast Track Designation to Vor Biopharma Product
September 10 2021 - 3:32AM
Dow Jones News
By Sabela Ojea
PureTech Health PLC said Friday that a product of its founded
entity Vor Biopharma Inc. has been granted fast track designation
by the U.S. Food and Drug Administration.
The London-listed biotechnology company said Vor Biopharma's
VOR33 lead engineered stem cell is now a therapeutic candidate for
the treatment of acute myeloid leukemia.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
September 10, 2021 03:17 ET (07:17 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024